Journal
AGING-US
Volume 12, Issue 19, Pages 18797-18803Publisher
IMPACT JOURNALS LLC
DOI: 10.18632/aging.104166
Keywords
coronavirus; viral spike glycoprotein; vaccine; common cold; COVID-19
Categories
Funding
- Lunella Biotech, Inc.
Ask authors/readers for more resources
Three recent papers published in Nature, Science and Cell, all present clear evidence that there is cross-reactive T-cell immunity between human coronaviruses (229E, NL63, OC43, and HKU1), linked with the common cold, and SARS-CoV-2, the causative agent of COVID-19. Can we use this information to design and build a new vaccine based on the less pathogenic, common cold coronaviruses, for the prevention of COVID-19? If we look at the history of medicine and vaccine development, from the point of view of Edward Jenner, the answer just might be yes.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available